Answers are grounded in this paper and cite their sources.
Review highlights developments in dopamine receptor ligands, suggesting implications for drug discovery.
High Resolution Image Download MS PowerPoint Slide Dopamine receptors (DRs) have been implicated in numerous disorders and diseases (e.g., Alzheimer’s disease, Parkinson’s disease, schizophrenia, and substance use disorders) and have served as attractive drug targets for these ailments. Despite their potential clinical utility, the development of selective DR ligands has been challenging due to difficulties in selectivity among the DR subtypes as well as other biogenic amine receptors and poor pharmacokinetic properties. The realization of their full potential necessitates continued advancements in DR ligands as investigative tools. This review aims to highlight the recent developments made in the chemical biology of DR ligands (e.g., bivalent ligands, photoactivatable ligands, photoswitchable probes, and fluorescent probes).
No takes yet. Share an insight, caveat, or question.
Dorogan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: